Almelo

What Almelo does

Almelo Private Limited is a Hyderabad, India-based pharmaceutical products manufacturer operating across four sites in Telangana: the Almelo Research Center (ARC) in-house R&D facility, APL Unit 1 (IDA-Kukatpally) for advanced intermediates and KSMs, APL Unit 2 (Medak, 65 acres) for active pharmaceutical ingredient production, and HAPL (IDA Mankhal) for specialty fine chemicals. The company was founded by T.S. Prasad and has been operating for 40+ years, with corporate establishment dated 1986 and the first manufacturing site constructed in 1979. Almelo produces APIs including Ranolazine, Pregabalin, Sugammadex Sodium, Dolutegravir Sodium, Levocetirizine DI-HCL, and Empagliflozin; an extensive catalog of advanced intermediates and KSMs; and specialty fine chemicals such as Dess-Martin Periodinane and Di-Tertbutyl Chloromethyl Phosphate. Operations run on Quality by Design principles with GAMP 5 compliant, Distributed Control System-enabled manufacturing lines.

Almelo's defining operating logic is vertical integration: HAPL supplies specialty fine chemicals and hazardous intermediates primarily for captive use, feeding APL Unit 1's intermediates/KSMs production, which in turn feeds APL Unit 2's API manufacturing. This chain is intended to secure supply stability, quality consistency, and cost competitiveness across the portfolio. Regulatory positioning is global, with US FDA Drug Master File filings, EU CEPs, Japan PMDA Foreign Manufacturer certification, WHO GMP certification, and ISO 9001/14001 plus OHSAS 18001 compliance. Facilities are designed against ICH 2022 working draft guidelines, and the R&D center offers custom services spanning process development, analytical method development, scale-up, technology transfer, impurity isolation and characterization, and genotoxicity evaluation.

Commercially, Almelo operates as a sales-led B2B ingredients manufacturer. It supplies directly to global pharmaceutical manufacturers through direct sales supported by a regulatory affairs department handling multi-jurisdictional filings. The corporate group is founder-owned, with T.S. Prasad as Founder and Managing Director, Anand Tatambhotla (IIT Bombay Chemical Engineering, Cambridge MBA) as Executive Director of Operations, and Dr. KeshavDeo (Head of R&D, 350+ patents) leading ARC. Pricing is quote-based and not publicly disclosed. The company is private with no disclosed external investors, parent entity, funding rounds, or M&A history in the available data.

Name

Almelo

Legal name

Almelo Private Limited

Website

https://almelochem.com

Company type

Private

Founded year

1986

Operating status

Operating

Headcount range

51–100 employees

Short description

Almelo Private Limited is a Hyderabad-based, vertically integrated pharmaceutical manufacturer producing active pharmaceutical ingredients, advanced intermediates, KSMs, and specialty fine chemicals for global drug makers from four cGMP-certified facilities with US FDA, EU CEP, WHO GMP, and Japan PMDA approvals.

Ownership category

akta.pro rank

Product category

Pharmaceutical Ingredients Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Chemical Manufacturing (325)

SIC

Chemicals & Allied Products (2800), Industrial Organic Chemicals (2860)

akta.pro primary industry

Small-Molecule API Commercial Manufacturing (HLAGAHAB)

Keywords

• Active pharmaceutical ingredients
• Pharmaceutical intermediates manufacturing
• Key starting materials
• Specialty fine chemicals
• Custom pharmaceutical R&D services

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Infrastructure, Technology or R&D, Personnel, Supply Chain

Revenue model

1. Active Pharmaceutical Ingredients (APIs): Manufacture and sale of pharmaceutical active ingredients including Ranolazine, Pregabalin, Sugammadex Sodium, Dolutegravir Sodium, Levocetirizine, Empagliflozin, and other APIs. Revenue generated through direct B2B sales to pharmaceutical companies with various regulatory filings including US DMF, EU ASMF, CEP, and other country-specific registrations.
2. Advanced Intermediates and KSMs: Manufacturing of advanced intermediates and Key Starting Materials (KSMs) for pharmaceutical applications. These are supplied to pharmaceutical manufacturers for use in their production processes.
3. Specialty Fine Chemicals: Production of specialty fine chemicals, complex side-chains, and hazardous intermediates primarily for captive consumption by Almelo Group with some external sales.
4. Custom R&D Services: Custom product R&D services offered by the Almelo Research Center including process development, analytical method development, scale-up, technology transfer, impurity isolation and characterization, and genotoxicity evaluation.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Almelo manufactures and sells Active Pharmaceutical Ingredients (APIs), advanced pharmaceutical intermediates, Key Starting Materials (KSMs), and specialty fine chemicals to pharmaceutical companies worldwide. The company operates four facilities (ARC, HAPL, APL Unit 1, APL Unit 2) providing fully backward-integrated supply from fine chemicals to APIs, supported by custom R&D services including process development, analytical method development, scale-up, technology transfer, and impurity characterization.

Product overview

Almelo Private Limited is a multi-specialty drug manufacturing company with 40 years in the pharmaceutical industry, offering a vertically integrated portfolio of Active Pharmaceutical Ingredients (APIs), Specialty Fine Chemicals, and Intermediates/KSMs. The company operates four manufacturing facilities: the Almelo Research Center (ARC) for R&D services, HAPL for specialty fine chemicals, APL Unit 1 for advanced intermediates and KSMs, and APL Unit 2 for API manufacturing. Services include automated GAMP 5-compliant manufacturing and completely backward-integrated supply chain capabilities.

Differentiator

Problem solved

Functional benefit

Products and services

• Active Pharmaceutical Ingredients (APIs) Active Pharmaceutical Ingredients manufactured at APL Unit 2, including Ranolazine, Pregabalin, Sugammadex Sodium, Dolutegravir Sodium, Levocetirizine DI-HCL, Empagliflozin, and additional APIs at various regulatory stages, with filings including US FDA DMF, EU ASMF, and country-specific registrations. Targeted at global pharmaceutical manufacturers requiring compliant APIs for drug formulation.
• Advanced Pharmaceutical Intermediates and Key Starting Materials (KSMs) Advanced pharmaceutical intermediates and Key Starting Materials manufactured at APL Unit 1, including intermediates for Alfuzosin, Avibactam, Azilsartan, Dabigatran, Dolutegravir, and many more, supplied with CAS numbers and end-use specifications to pharmaceutical manufacturers for use in drug synthesis.
• Specialty Fine Chemicals Specialty fine chemicals, complex side-chains, and hazardous intermediates manufactured at the HAPL facility, including Di-Tertbutyl Chloromethyl Phosphate, Potassium Di-Tertiary Butyl Phosphate, Pyridinium Para Toluene Sulfonate, Dess-Martin Periodinane, and others, primarily for captive consumption within Almelo Group with selective external sales.
• Almelo Research Center (ARC) Custom R&D Services In-house R&D center providing custom pharmaceutical product R&D services including process development, analytical method development, scale-up, technology transfer, impurity isolation and characterization, and genotoxicity evaluation, staffed by 35+ scientists and engineers including 9 PhDs.
• Automated Manufacturing (GAMP 5 Compliant DCS-Enabled Production) GAMP 5 compliant, Distributed Control System (DCS)-enabled manufacturing line providing consistent quality output batch over batch with precise control over operating parameters.
• Completely Backward-Integrated Manufacturing Vertically integrated manufacturing facilities that are both independent and integrable, starting from fine chemicals to advanced pharmaceutical intermediates to APIs, ensuring supply chain stability and cost competitiveness for pharmaceutical customers.

Quantifiable outcome

• 40 years of pharmaceutical industry experience
• +3 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators6 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Laurus Labs: Indian API and intermediate manufacturer with deep backward integration, supplying global generic and branded pharma. Mirrors Almelo's model of starting from intermediates/KSMs and producing commercial APIs under US FDA and EU GMP filings.
• Suven Life Sciences: Indian CRAMS/CDMO and API player with research-led operations and US DMF/EU filings. Comparable to Almelo on small-molecule intermediates and API manufacturing with a strong research and patent footprint.
• MSN Laboratories: Privately held Indian API and intermediate manufacturer with multi-site facilities and global regulatory approvals. Closely comparable on API+intermediate+custom research scope, mid-market scale, and Indian private-company operating profile.
• Divis Laboratories: India-based, publicly listed manufacturer of APIs, intermediates and a custom synthesis (CDMO) business. Directly comparable to Almelo on small-molecule API manufacturing, backward-integrated intermediates, and global regulatory filings (US FDA, EU GMP).
• Neuland Laboratories: Mid-sized Indian API and intermediate manufacturer focused on small-molecule complex chemistries, with US DMF/EDMF filings and custom synthesis services — a close size and product-mix analog to Almelo.

Broad incumbents

• Granules India: Indian pharmaceutical manufacturer with APIs and finished dosages, holding US FDA, EU GMP and WHO GMP approvals. Overlaps with Almelo in API supply into global generic channels and offers a relevant comparable on regulatory positioning and scale.
• Piramal Pharma Solutions: Large global CDMO offering integrated API, intermediates and drug product services. Competes with Almelo at the high end of the Indian API/CDMO market and offers broader end-to-end development capability.
• Aurobindo Pharma: Vertically integrated Indian pharma with a large API business and direct US FDA/EU filings. Provides an upper bound on size and represents the broader incumbent competitive context for Almelo's API offerings.

Emerging players

• Sai Life Sciences: India-headquartered CDMO offering small-molecule API and intermediate development and manufacturing. Comparable to Almelo on chemistry complexity, custom synthesis and Indian operating base, with a stronger CDMO tilt.

Others

• Mettler-Toledo (process analytics for pharma manufacturing): Not a competitor but an enabling technology vendor whose process analytical and automation technologies underpin GAMP 5 / QbD-style API plants like Almelo's. Useful as an adjacency reference for technology-driven pharma manufacturing.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/almelo-group-of-companies

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Almelo